# Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL

> **NCT04491721** · — · ENROLLING_BY_INVITATION · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 407 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04491721
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2020-07
- **Primary completion:** 2027-06
- **Final completion:** 2027-07
- **Target enrollment:** 407 (ESTIMATED)
- **Last updated:** 2020-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04491721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04491721, "Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT04491721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*